Candidate biomarkers predictive of anthracycline and taxane efficacy against breast cancer

( Max 2000 Items )
URI http://shark.lib.kagawa-u.ac.jp/kuir/metadata/28446
Title
Candidate biomarkers predictive of anthracycline and taxane efficacy against breast cancer
File
Description

Abstract
Background:

Since breast cancer shows diversity in clinical behaviors, a standard therapy does not always lead to favorable outcomes.
Materials and Methods:

The expression statuses of candidate markers, including topoisomerase-II alpha (TOP2A), beta-tubulin (B-tub), and tissue inhibitor of metalloprotease-1 (TIMP-1), were immunohistochemically evaluated in 70 breast cancer tissues from 68 patients with advanced breast cancers receiving chemotherapy.
Results:

The response rates to anthracycline and taxane were 70.5% and 67.2%, respectively. Overall, 25.1% ± 29.7%, 8.32% ± 10.1%, and 16.37% ±17.5% of cancer cells in the tumors studied were positive for B-tub, TOP2A, and TIMP-1 expressions, respectively. However, positive molecule expression did not differ between patients who did and did not exhibit clinical responses to treatment. The proportion of TOP2A-positive cancer cells was significantly higher among anthracycline responders than among nonresponders in HR-negative cancer (15.4% ±17.5% vs. 2.0% ± 2.4%, respectively, P = 0.048), whereas TOP2A and TIMP-1 expression statuses did not differ in HR-positive cancer. When patients were stratified according to B-tub, TOP2A, or TIMP-1 expression statuses (B-tub ≥10% vs. <10%, TOP2A ≥5% vs. <5%, TIMP-1 ≤20% vs. >20%, respectively), the proportion of patients with ≥10% B-tub-positive cancer cells was significantly higher in taxane responders than in nonresponders (72.4% vs. 37.5%, respectively, P = 0.016). Anthracycline responders showed a trend to have a higher proportion of patients with either ≥5% TOP2A-positive cancer cells or ≤20% TIMP-1-positive cancer cells compared to nonresponders (86.7% vs. 61.5%, respectively, P = 0.066).
Conclusion:

Immunohistochemical TOP2A, TIMP-1, and B-tub expression analyses are expected to be useful for predicting tumor responses to chemotherapy.

KEYWORDS:

Anthracycline; beta-tubulin; breast cancer; predictive biomarker; taxane; tissue inhibitor of metalloprotease-1; topoisomerase-II alpha

(医博甲675)

Author
著者 法村 尚子
著者(ヨミ) ノリムラ ショウコ
著者(別表記) Norimura Shoko
Publication Title
Journal of Cancer Research and Therapeutics
Publication Title Alternative
J Cancer Res Ther.
Volume
14
Issue
2
Start Page
409
End Page
415
Publisher
Association of Radiation Oncology of India
Medknow Publications
Published Date
2018
ISSN
0973-1482
NCID
AA12058433
PMID
29516929
DOI
10.4103/jcrt.JCRT_1053_16
Resource Type
Thesis or Dissertation
Language
eng
Relation
出版社版DOIリンク(URL): https://doi.org/10.4103/jcrt.JCRT_1053_16
Resource URL
https://doi.org/10.4103/jcrt.JCRT_1053_16
Rights
Copyright © 2018, Wolters Kluwer Medknow Publications
This article is available under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike License (CC BY-NC-SA), which permits non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. Permission only needs to be obtained for commercial use.
DOI: https://doi.org/10.4103/jcrt.JCRT_1053_16
Text Version
ETD
Grant ID
博甲第675号
Grant Date
2017-12-27
Degree Name
博士(医学)
Grantor
香川大学
Set
香川大学
Copyright (C) 2009 Kagawa University All rights reserved.